Last updated: February 25, 2026
What is NDC 68180-0433?
NDC 68180-0433 identifies Rituximab (brand name: Rituxan), a monoclonal antibody indicated for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases. It is marketed by Genentech, a member of Roche.
Market Size and Penetration
Market scope: Rituximab has been a core immunotherapy for hematologic cancers and autoimmune conditions since its FDA approval in 1997. Its global sales peaked at approximately $4.3 billion in 2021, driven primarily by the U.S., Europe, and select Asian markets.
Key drivers:
- Incidence rates for non-Hodgkin's lymphoma (NHL): Estimated at 19.8 per 100,000 in the U.S. (SEER Program, 2020).
- Rheumatoid arthritis prevalence: ~1%. An estimated 1.3 million adults in the U.S. (CDC, 2019).
- Competitive landscape: Includes biosimilars and alternative biologics such as Ofatumumab and Obinutuzumab.
Market share: As of 2022, Rituximab retained approximately 70% of the biologic market segment for NHL and RA, indicating limited biosimilar penetration due to patent protections and supply agreements.
Competition and Patent Landscape
- Patent exclusivity: Roche's key patents expired in 2018; however, secondary patents and formulation protections extend market rights until at least 2028.
- Biosimilar entries: Multiple biosimilars have received regulatory approval (e.g., Pfizer's Ruxience, Sandoz's Truxima) but faced delayed market entry due to legal and pricing strategies.
- Impact of biosimilars: Though initially limited, biosimilars are gaining ground, especially in European markets, reducing list prices by approximately 15-30%.
Pricing Trends and Projections
Current Pricing
- U.S. List Price: The average wholesale acquisition cost (WAC) for Rituximab is around $4,700 per 500 mg vial.
- Reimbursement Rates: Commercial insurers and Medicare Part B reimburse at approximately 85-95% of WAC, leading to net prices near $4,000 per dose.
Cost Dynamics
| Price Component |
Current Status |
Trends |
| WAC per vial |
~$4,700 / 500 mg |
Stable |
| Net reimbursement |
~$4,000 / dose |
Slight decline due to biosimilar competition |
| Biosimilar impact |
Introducing alternatives |
Expected to lower price by 15-30% over 3-5 years |
Projections (Next 5 Years)
- Price Decline: Biosimilars are projected to decrease Rituximab’s list price by 10-20% by 2027.
- Market share shifts: Biosymilars could capture 30-50% of the market in developed countries, exerting downward pricing pressure.
- Reimbursement adjustments: Payers may push for value-based contracts, encouraging discounts and value-based pricing.
Revenue Forecasts
| Year |
Estimated U.S. Sales |
Key Factors |
| 2023 |
~$3.8 billion |
Patents projected to expire |
| 2024 |
~$3.5 billion |
Biosimilar launches continue |
| 2025 |
~$3.2 billion |
Increased biosimilar market penetration |
| 2026 |
~$2.9 billion |
Price reductions solidify |
| 2027 |
~$2.7 billion |
Market stabilization |
Supply Chain and Regulatory Influences
- Supply: Roche maintains quality manufacturing, with potential capacity increases to meet rising biosimilar competition.
- Regulatory landscape: Biosimilar approval pathways in the U.S. via the Biologics Price Competition and Innovation Act (BPCIA) remain competitive, opening markets in Europe, Asia, and Latin America.
Key Takeaways
- The market for Rituximab is mature, with sustained demand driven by indications such as NHL and RA.
- Patent expirations and biosimilar developments are reducing prices, with an expected 10-20% decline over five years.
- The overall market remains sizable, with annual sales potentially decreasing from ~$4 billion to below $3 billion in the U.S. due to biosimilar competition.
- Pricing strategies and reimbursement policies will significantly influence net revenue trends.
- Roche's ongoing patent protections and formulation innovations may delay full biosimilar market impact until approximately 2028.
FAQs
Q1: What are the primary drivers for Rituximab's market decline?
Patent expiration and biosimilar entry reduce list prices and market share.
Q2: How does biosimilar competition affect Rituximab prices?
Biosimilars typically lower prices by approximately 15-30%, pressuring originator prices and reimbursement rates.
Q3: What are the main indications influencing market volume?
Non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Q4: What is the outlook for Rituximab's global sales?
Global sales are projected to decline gradually as biosimilars penetrate markets outside the U.S., where patent protections end.
Q5: Which factors could alter these projections?
Regulatory changes, patent litigation outcomes, manufacturing disruptions, or new therapeutic alternatives could shift the market trajectory.
References
- SEER Program. (2020). Cancer statistics review. National Cancer Institute.
- CDC. (2019). Rheumatoid arthritis prevalence. Centers for Disease Control and Prevention.
- IQVIA. (2022). Biologic Market Report. IQVIA Holdings Inc.
- U.S. Food and Drug Administration. (2022). Biosimilar approvals.
- European Medicines Agency. (2022). Biosimilar market updates.
Note: Data compiled from publicly available market reports and regulatory filings as of early 2023.
